Basal Cell Neoplasms Pipeline

DelveInsight’s, “Basal Cell Neoplasms Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Basal Cell Neoplasms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Basal Cell Neoplasms: Understanding

Basal Cell Neoplasms: Overview

Basal cell neoplasms, commonly referred to as basal cell carcinomas (BCCs), are the most common form of skin cancer. These tumors arise from the basal cells, which are located in the lowest layer of the epidermis. While BCCs are typically slow-growing and rarely metastasize, they can be locally invasive and cause significant damage to surrounding tissues if not treated. BCCs are most frequently found in sun-exposed areas of the skin, such as the face, neck, and hands, and their incidence increases with age and cumulative sun exposure.

 

The signs and symptoms of basal cell neoplasms can vary but often include the appearance of a new growth or sore that does not heal. The lesions may appear as pearly or waxy bumps, often with visible blood vessels (telangiectasia) on the surface. Other presentations include flat, scaly, reddish patches, or open sores that may bleed or crust over. Sometimes, BCCs may appear as scar-like areas with poorly defined borders. These growths are usually painless, but they can become tender or itchy, especially if they ulcerate. The primary cause of basal cell neoplasms is long-term exposure to ultraviolet (UV) radiation from the sun or tanning beds, which leads to DNA damage in skin cells. Individuals with fair skin, light-colored eyes, and a history of frequent sunburns are at higher risk. Genetic predispositions, such as mutations in the PTCH1 gene (associated with Gorlin syndrome), can also increase susceptibility to BCCs.

 

Pathophysiologically, the mutation in the DNA of basal cells leads to uncontrolled cell growth, resulting in the formation of neoplasms. These tumors typically remain localized to the skin but can invade deeper tissues if left untreated.

Diagnosis of basal cell neoplasms is usually made through a combination of clinical examination and biopsy. A dermatologist may suspect BCC based on the appearance of the lesion and will confirm the diagnosis with a skin biopsy, where a sample of the lesion is examined under a microscope. Treatment options vary depending on the size, location, and subtype of the BCC, as well as the patient's overall health. Common treatments include surgical excision, Mohs micrographic surgery (which involves removing the tumor layer by layer while preserving healthy tissue), and cryotherapy. Non-surgical options like topical treatments, photodynamic therapy, and radiation therapy may also be used in certain cases.

In summary, while basal cell neoplasms are generally slow-growing and non-metastatic, they require prompt diagnosis and treatment to prevent local tissue destruction. Early intervention, especially for lesions in cosmetically sensitive areas, can lead to better outcomes and reduce the risk of recurrence. Preventive measures, including sun protection and regular skin checks, are crucial for reducing the incidence of BCCs.

 

"Basal Cell Neoplasms Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Basal Cell Neoplasms pipeline landscape is provided which includes the disease overview and Basal Cell Neoplasms treatment guidelines. The assessment part of the report embraces, in depth Basal Cell Neoplasms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Basal Cell Neoplasms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Basal Cell Neoplasms R&D. The therapies under development are focused on novel approaches to treat/improve Basal Cell Neoplasms.

Basal Cell Neoplasms Recent Developments:

• In April 2025, Senhwa Biosciences, Inc. announced the completion of Clinical Study Report (CSR) for Phase I/Dose Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma(BCC), with positive data outcomes. CX-4945 significantly prolonged survival in advanced cancer patients, marking a major milestone for both the patients and Senhwa.
• In April 2025, Zynext Ventures, the venture capital arm of Zydus Lifesciences (Zydus) announced its investment in Feldan Therapeutics for the development of treatments based on intracellular delivery of therapeutics.
• In January 2025, Rise Therapeutics announced that the US Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase I clinical trial for its program candidate, R-5780.
• In January 2025, Stamford Pharmaceuticals announced positive results from Phase II Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients.
• In January 2025, Verrica Pharmaceuticals Inc. announced positive topline findings from part 2 of its Phase II study on VP-315 at the 2025 Winter Clinical Miami Dermatology Conference, held January 17-19, 2025, in Miami, Florida.

Basal Cell Neoplasms Emerging Drugs Chapters

This segment of the Basal Cell Neoplasms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Basal Cell Neoplasms Emerging Drugs

• Patidegib: Sol-Gel Technologies

Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors. Currently, the drug is in the Phase III stage of its development for the treatment of Basal Cell Carcinoma.

 

• AIV001: AiViva BioPharma, Inc.

AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. In nonclinical in vivo studies, AIV001 demonstrated reduced dermal neovascularization and fibroplasia in wound healing models and long residence time in the skin with a single treatment. AiViva has completed a Phase I/IIa clinical trial of AIV001 for the incisional scarring and wound healing and has completed a clinical trial for nonmelanoma skin cancer.

Further product details are provided in the report……..

 

Basal Cell Neoplasms: Therapeutic Assessment

This segment of the report provides insights about the different Basal Cell Neoplasms drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Basal Cell Neoplasms

There are approx. 25+ key companies which are developing the therapies for Basal Cell Neoplasms. The companies which have their Basal Cell Neoplasms drug candidates in the most advanced stage, i.e. Phase III include, Sol-Gel Technologies.

 

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Basal Cell Neoplasms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Basal Cell Neoplasms Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Patidegib	Sol-Gel Technologies	III	SMO protein inhibitors	Topical
VP-315	Lytix Biopharma/Verrica Pharmaceuticals	III	Immunostimulants	Intratumoral
AIV001	AiViva BioPharma, Inc.	I/II	Tyrosine kinase inhibitor	Intradermal/intratumoral
FLD-103	Feldan Therapeutics	I/II	Zinc finger protein GLI1 inhibitors	Intralesional
Silmitasertib	Senhwa Biosciences	I	Casein kinase II inhibitors	Oral
AVX001	Coegin Pharma AB	I	Phospholipase A2 modulators	Topical

 

Basal Cell Neoplasms Pipeline Development Activities 

The Basal Cell Neoplasms pipeline report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Basal Cell Neoplasms therapeutic drugs key players involved in developing key drugs.

Basal Cell Neoplasms Pipeline Development Activities

The Basal Cell Neoplasms clinical trials report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal Cell Neoplasms drugs.

Unlock comprehensive insights into Basal Cell Neoplasms market, epidemiology, and forecasts till 2034—explore growth opportunities today!

Basal Cell Neoplasms Report Insights

• Basal Cell Neoplasms Pipeline Analysis
• Basal Cell Neoplasms Therapeutic Assessment
• Basal Cell Neoplasms Unmet Needs
• Impact of Basal Cell Neoplasms Drugs

 

Basal Cell Neoplasms Report Assessment

• Basal Cell Neoplasms Pipeline Product Profiles
• Basal Cell Neoplasms Therapeutic Assessment
• Basal Cell Neoplasms Pipeline Assessment
• Inactive drugs assessment
• Basal Cell Neoplasms Unmet Needs

 

Key Questions Answered In The Basal Cell Neoplasms Pipeline Report:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Basal Cell Neoplasms drugs?
• How many Basal Cell Neoplasms drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal Cell Neoplasms?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Basal Cell Neoplasms therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Basal Cell Neoplasms and their status?
• What are the key designations that have been granted to the emerging drugs?